Amarna Therapeutics

Amarna Therapeutics is a privately held European biotechnology company developing the next generation of viral vector platforms, which can play a crucial role in transforming treatments across many disease areas. Amarna is the first company to successfully develop SVac, a viral vector platform derived from Simian Virus 40 (SV40). Amarna produces SVac vector particles using its proprietary SuperVero-derived cell line. One of the key barriers to the biologics revolution has been the development of efficient delivery systems. Viral vectors, and more specifically, delivery platforms based on SV40, appear to be the best approach, but until Amarna, no one had been able to develop a viable production system. Unlike other delivery systems, SVac is non-immunogenic, capable of targeting various cell types and tissues, and can be produced at scale. Therefore, it offers significant advantages over other viral vectors, which are inefficient, immunogenic, and difficult to produce in the quantities required for commercialization. For patients, SVac-based therapies represent a paradigm shift. A single administration of SVac provides long-lasting therapeutic effects compared to current treatment regimens. Amarna Therapeutics B.V. was founded in 2008 and is headquartered in Leiden, the Netherlands, with R&D and manufacturing facilities in the Netherlands and Spain.